On the evening of July 10th, Foresee Pharmaceuticals announced that its new formulation of the prostate cancer drug Camcevi 42mg (six-month extended-release injection) has received market approval in Israel. This medication will be used to treat adult patients with advanced prostate cancer.

Foresee Pharmaceuticals disclosed that its licensing partner, Megapharm, submitted the Marketing Authorization Application (MAA) for Camcevi 42mg (FP-001 50mg) to the Israeli Ministry of Health (MOH) on April 4, 2022. On May 12, 2022, they received a notification from the MOH that the application had passed the preliminary review and had entered the substantive review phase.

Foresee Pharmaceuticals announced that they received notification from Megapharm on July 10th of this year that the Israeli Ministry of Health had completed its review of the Camcevi 42mg injection and granted market approval.

Foresee Pharmaceuticals highlighted that with the aging population, the number of prostate cancer patients is steadily increasing. According to Nova One Advisor, the global market for prostate cancer therapeutics was approximately $15.2 billion in 2021 and is expected to grow to $24.9 billion by 2030, with an estimated compound annual growth rate (CAGR) of 9.4%.

Data from Precision Reports indicates that the global market value of leuprolide, for all indications, was approximately $2.455 billion in 2021 and is projected to reach $3.264 billion by 2027, with an estimated CAGR of 4.86%.

Foresee Pharmaceuticals's Camcevi 42mg is a pre-filled six-month extended-release injection developed using their proprietary sustained-release injection platform technology. This innovation addresses the inconvenience and potential usage errors associated with the manual mixing required by high-activity leuprolide injections over the past 30 years.

Resource (mandarin): 逸達前列腺癌新劑型藥 Camcevi 42毫克獲以色列上市許可